NVO

69.46

1.25% 0.86

Pre-mercato: 69.11 -0.35 -0.50%

Novo Nordisk Adr (NVO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Perché NVO Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$68.60

Aprire:

$69.26

Volume 24 ore:

8.98M

Relative Volume:

0.96

Capitalizzazione di mercato:

$235.48B

Reddito:

$43.59B

Utile/perdita netta:

$15.04B

Rapporto P/E:

20.57

EPS:

3.3766

Flusso di cassa netto:

$10.74B

1 W Prestazione:

+1.89%

1M Prestazione:

+6.60%

6M Prestazione:

-34.96%

1 anno Prestazione:

-47.65%

Intervallo 1D:

$68.30

$69.50

Intervallo di 1 settimana:

$66.60

$71.30

Portata 52W:

$57.00

$148.15

Novo Nordisk Adr Stock (NVO) Company Profile

Nome

Novo Nordisk Adr

Settore

Healthcare (1177)

Industria

Drug Manufacturers - General (20)

Telefono

Indirizzo

Dipendente

77,406

Cinguettio

@novonordisk

Prossima data di guadagno

2024-12-06

Ultimi documenti SEC

NVO's Discussions on Twitter

Confronta NVO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NVO Novo Nordisk Adr	69.46	302.90B	43.59B	15.04B	10.74B	3.3766
LLY Lilly Eli Co	722.57	642.06B	49.00B	11.11B	-1.27B	12.29
JNJ Johnson Johnson	153.58	367.19B	89.33B	21.81B	18.57B	8.99
ABBV Abbvie Inc	185.62	322.44B	57.37B	4.20B	15.39B	2.35
NVS Novartis Ag Adr	112.58	222.20B	53.22B	12.86B	14.85B	6.39

Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-04-17	Downgrade	BMO Capital Markets	Outperform → Market Perform
2025-03-13	Aggiornamento	Kepler	Hold → Buy
2025-03-03	Downgrade	Stifel	Buy → Hold
2025-02-12	Iniziato	Morgan Stanley	Equal-Weight
2025-01-06	Aggiornamento	Bernstein	Underperform → Mkt Perform
2024-05-30	Iniziato	Goldman	Buy
2024-04-12	Iniziato	BMO Capital Markets	Outperform
2024-01-23	Iniziato	Morgan Stanley	Overweight
2024-01-16	Ripresa	UBS	Neutral
2023-12-01	Iniziato	Cantor Fitzgerald	Overweight
2023-10-02	Iniziato	Argus	Buy
2023-07-14	Iniziato	HSBC Securities	Buy
2022-07-15	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-06-28	Downgrade	UBS	Neutral → Sell
2022-06-27	Aggiornamento	Exane BNP Paribas	Underperform → Neutral
2022-06-07	Aggiornamento	JP Morgan	Neutral → Overweight
2022-05-31	Aggiornamento	Guggenheim	Neutral → Buy
2022-04-25	Aggiornamento	Cowen	Market Perform → Outperform
2022-04-12	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2022-03-16	Aggiornamento	Deutsche Bank	Hold → Buy
2022-01-25	Downgrade	Liberum	Hold → Sell
2021-12-20	Downgrade	JP Morgan	Overweight → Neutral
2021-12-17	Downgrade	Deutsche Bank	Buy → Hold
2021-01-20	Downgrade	Credit Suisse	Outperform → Neutral
2021-01-15	Iniziato	Deutsche Bank	Buy
2020-09-29	Iniziato	Berenberg	Hold
2020-07-06	Downgrade	BofA Securities	Buy → Neutral
2020-05-11	Downgrade	UBS	Buy → Neutral
2020-05-04	Iniziato	Cowen	Market Perform
2020-03-16	Aggiornamento	BofA/Merrill	Neutral → Buy
2020-01-03	Downgrade	Guggenheim	Buy → Neutral
2019-11-18	Aggiornamento	Barclays	Equal Weight → Overweight
2019-09-17	Aggiornamento	Citigroup	Neutral → Buy
2019-08-30	Downgrade	Jefferies	Hold → Underperform
2019-06-20	Downgrade	Deutsche Bank	Buy → Hold
2019-06-11	Aggiornamento	Barclays	Underweight → Equal Weight
2019-04-29	Aggiornamento	Credit Suisse	Neutral → Outperform
2019-01-29	Iniziato	Exane BNP Paribas	Outperform
2018-12-11	Ripresa	Jefferies	Hold
2018-10-09	Iniziato	Guggenheim	Buy
2017-12-29	Aggiornamento	JP Morgan	Underweight → Neutral
2017-12-06	Aggiornamento	BofA/Merrill	Neutral → Buy
2017-12-01	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2017-09-25	Downgrade	Exane BNP Paribas	Outperform → Neutral
2017-09-06	Aggiornamento	BofA/Merrill	Underperform → Neutral

Mostra tutto

Novo Nordisk Adr Borsa (NVO) Ultime notizie

May 29, 2025

Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.

May 29, 2025

May 19, 2025

Novo Nordisk Faces Obesity Competition, but Innovation Still Warrants a Wide Moat - Morningstar

May 19, 2025

Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.

May 19, 2025

May 16, 2025

European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize

May 16, 2025

May 13, 2025

What Did We Find About Insider Trading At Novo Nordisk ADR (NYSE: NVO)? - Stocksregister

May 13, 2025

May 09, 2025

Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up - MSN

May 09, 2025

May 08, 2025

Novo Nordisk ADR earnings beat by $5.64, revenue topped estimates - Investing.com Nigeria

May 08, 2025

May 07, 2025

Novo Nordisk Earnings: Compounders Pressured Q1 Wegovy Sales - Morningstar

May 07, 2025

Novo Nordisk Earnings: Compounders Pressured Q1 Wegovy Sales, but Strategy Should Preserve Growth - Morningstar

May 07, 2025

European ADRs See Mixed Results With Modest Gains - Finimize

May 07, 2025

Novo Nordisk expects U.S. sales of Wegovy weight-loss drug to recover soon, CEO says - The Globe and Mail

May 07, 2025

Market news - investments.halifax.co.uk

May 07, 2025

Novo Nordisk cuts guidance but says generic competition will ease - Sharecast.com

May 07, 2025

May 06, 2025

European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize

Apr 30, 2025

Apr 29, 2025